ACORQ Stock - Acorda Therapeutics, Inc.
Unlock GoAI Insights for ACORQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $117.63M | $118.57M | $129.07M | $152.97M | $192.41M |
| Gross Profit | $71.59M | $57.47M | $57.52M | $88.69M | $131.92M |
| Gross Margin | 60.9% | 48.5% | 44.6% | 58.0% | 68.6% |
| Operating Income | $-23,264,000 | $-54,290,000 | $-71,299,000 | $-86,554,000 | $-116,605,000 |
| Net Income | $-252,854,000 | $-65,916,000 | $-103,954,000 | $-99,594,000 | $-272,966,000 |
| Net Margin | -215.0% | -55.6% | -80.5% | -65.1% | -141.9% |
| EPS | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Visit WebsiteEarnings History & Surprises
ACORQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 14, 2024 | — | $-22.06 | — | — |
Q2 2024 | Apr 1, 2024 | — | $-225.81 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-7.16 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-7.55 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-13.83 | — | — |
Q4 2022 | Dec 31, 2022 | $-3.00 | $8.76 | +392.0% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-2.00 | $-11.41 | -470.4% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | — | $-55.63 | — | — |
Q1 2022 | Mar 30, 2022 | $-7.20 | $-37.01 | -414.0% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $-34.69 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-48.64 | — | — |
Latest News
Frequently Asked Questions about ACORQ
What is ACORQ's current stock price?
What is the analyst price target for ACORQ?
What sector is Acorda Therapeutics, Inc. in?
What is ACORQ's market cap?
Does ACORQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ACORQ for comparison